Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexington Biosciences Holdings Corp LXGTF

Financial Services Asset Management
Lexington Biosciences Holdings Corp., formerly Lexington Biosciences Inc., is a Canada-based medical device company, which core business is to develop and commercialize non-invasive diagnostic product HeartSentry to monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of a person’s cardiovascular system. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The company is in the final stages of releasing the developed product for clinical studies. The Company's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.


GREY:LXGTF - Post by User

Lexington Biosciences Holdings Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Post by CatamaranFundon Feb 18, 2019 1:57am
190 Views
Post# 29378337

Lexington Bio Announces Termination of Private Placement

Lexington Bio Announces Termination of Private PlacementLooks like  Placement did not go well at all for Lexington according to recent news report from Seeking Alpha link:

Lexington Biosciences Announces Termination of Private Placement

VANCOUVER, British Columbia, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”) announces that, despite numerous attempts over the past 9 months, it has been unable to secure the necessary funding to advance the development of its HeartSentry technology. As a result, the Company is terminating its previously announced private placement and will be reviewing its strategic options going forward.
 
On Behalf of the Board,
 
“Eric Willis”
 
Eric Willis
CEO & Director
https://seekingalpha.com/pr/17413804-lexington-biosciences-announces-termination-private-placement

As a recent stroke survivor - i am a bit saddened to read this but hope that maybe they can find a Joint venture partner as i believe they have proactive & preventative technology that is needed to help identify and reduce those who are at high risk of heart attacks and strokes.

Anyone else have any comments on this news or on the future of Lexington Biosciences?

Cheers to all investors.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities